Parabilis Medicines, Inc. (PBLS) Balance Sheet
PBLS balance sheet, 2025
December 31, 2025 · U.S. dollars$80.8M assets = $97.3M liabilities + −$16.5M equity
Liabilities exceed assets: shareholders’ equity is negative (−$16.5M).
Both columns are drawn to the same scale: what PBLS owns equals what it owes plus shareholders’ equity. Hover a block for its value.
PBLS financial health
Descriptive bands, not a rating. Fiscal 2025.
PBLS balance sheet trends, 2024–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $149.3M2024 | $80.8M2025 | −45.9%/yr | |
| Total liabilities | $92.8M2024 | $97.3M2025 | +4.9%/yr | |
| Shareholders’ equity | $56.4M2024 | −$16.5M2025 | — | |
| Cash & short-term investments | $88.0M2024 | $27.7M2025 | −68.5%/yr | |
| Total debt | $66.2M2024 | $58.7M2025 | −11.3%/yr | |
| Net cash (debt) | $21.8M2024 | −$31.0M2025 | −$52.8M | |
| Working capital | $59.8M2024 | −$27.4M2025 | −$87.2M | |
| Current ratio | 2.842024 | 0.522025 | −2.33 |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
PBLS assets
PBLS liabilities and equity
PBLS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
PBLS balance sheet
| 2025 | 2024 | |
|---|---|---|
| Assets | ||
| Cash & short-term investments | $27.7M | $88.0M |
| Cash & equivalents | $27.7M | $47.3M |
| Short-term investments | $0 | $40.7M |
| Receivables | $0 | $360,000 |
| Inventory | $0 | $0 |
| Other current assets | $1.6M | $3.9M |
| Total current assets | $29.4M | $92.2M |
| Property, plant & equipment (net) | $46.1M | $52.9M |
| Goodwill & intangible assets | $0 | $0 |
| Long-term investments | $0 | $0 |
| Other non-current assets | $5.4M | $4.1M |
| Total assets | $80.8M | $149.3M |
| Liabilities | ||
| Accounts payable | $17.3M | $9.5M |
| Short-term debt | $20.9M | $9.4M |
| Total current liabilities | $56.8M | $32.4M |
| Long-term debt | $0 | $12.8M |
| Lease obligations | $45.6M | $50.9M |
| Other long-term liabilities | $40.6M | $47.6M |
| Total liabilities | $97.3M | $92.8M |
| Shareholders' equity | ||
| Retained earnings (deficit) | −$541.5M | −$395.6M |
| Accumulated other comprehensive income | — | $21,000 |
| Total shareholders' equity | −$16.5M | $56.4M |
| Key figures | ||
| Total debt | $58.7M | $66.2M |
| Net cash (debt) | −$31.0M | $21.8M |
| Working capital | −$27.4M | $59.8M |
| Tangible book value | −$16.5M | $56.4M |
| Current ratio | 0.52 | 2.84 |
| Quick ratio | 0.49 | 2.73 |
| Debt / equity | — | 1.17 |
| Equity / assets | −20.4% | 37.8% |
| Jun '26 | Mar '26 | |
|---|---|---|
| Assets | ||
| Cash & short-term investments | $1.12B | $329.0M |
| Cash & equivalents | $1.09B | $329.0M |
| Short-term investments | $33.6M | — |
| Receivables | $0 | $0 |
| Inventory | $0 | $0 |
| Other current assets | $4.7M | $3.0M |
| Total current assets | $1.13B | $332.1M |
| Property, plant & equipment (net) | $42.7M | $44.4M |
| Goodwill & intangible assets | $0 | $0 |
| Long-term investments | $0 | $0 |
| Other non-current assets | $7.1M | $7.7M |
| Total assets | $1.18B | $384.2M |
| Liabilities | ||
| Accounts payable | $18.5M | $15.0M |
| Short-term debt | $14.0M | $17.4M |
| Deferred revenue | $10.4M | — |
| Total current liabilities | $62.8M | $54.2M |
| Long-term debt | $0 | $0 |
| Lease obligations | $41.8M | $43.7M |
| Other long-term liabilities | $64.7M | $85.7M |
| Total liabilities | $127.5M | $140.0M |
| Shareholders' equity | ||
| Common stock & paid-in capital | $12,000 | — |
| Retained earnings (deficit) | −$639.3M | −$586.8M |
| Accumulated other comprehensive income | −$18,000 | — |
| Total shareholders' equity | $1.05B | $244.2M |
| Key figures | ||
| Total debt | $47.5M | $53.1M |
| Net cash (debt) | $1.07B | $275.9M |
| Working capital | $1.06B | $277.8M |
| Tangible book value | $1.05B | $244.2M |
| Book value per share | $36.24 | — |
| Shares outstanding | 28.9M | — |
| Current ratio | 17.91 | 6.12 |
| Quick ratio | 17.83 | 6.07 |
| Debt / equity | 0.05 | 0.22 |
| Equity / assets | 89.1% | 63.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed December 31, 2025); data from EODHD.
PBLS financial position
At the end of fiscal 2025 (December 31, 2025), Parabilis Medicines had total assets of $80.8 million (down 45.9% from a year earlier), total liabilities of $97.3 million and shareholders' equity of -$16.5 million. It held $27.7 million in cash and short-term investments against $58.7 million of debt, net debt of $31.0 million. Its current ratio was 0.52. In the latest quarter (ended June 30, 2026) total assets were $1.2 billion and equity $1.0 billion.
Related: PBLS income statement, PBLS cash flow statement, PBLS key metrics. See the PBLS stock overview for the latest quote and news.
PBLS balance sheet FAQ
What are Parabilis Medicines's total assets?
Parabilis Medicines reported total assets of $80.8 million at the end of fiscal 2025 (December 31, 2025), compared with $149.3 million a year earlier.
How much debt does Parabilis Medicines have?
Parabilis Medicines had $58.7 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was —.
How much cash does Parabilis Medicines have?
Parabilis Medicines held $27.7 million in cash and short-term investments at the end of fiscal 2025; with $58.7 million of debt that is net debt of $31.0 million.
What is Parabilis Medicines's book value?
Parabilis Medicines's shareholders' equity (book value) was -$16.5 million at the end of fiscal 2025.
What is Parabilis Medicines's current ratio?
Parabilis Medicines had current assets of $29.4 million and current liabilities of $56.8 million, a current ratio of 0.52 (current liabilities exceed current assets).